Press Releases

10.31.2025

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

10.30.2025

Pfizer Addresses Proposal for Metsera

10.19.2025

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

10.19.2025

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

10.18.2025

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

10.14.2025

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

10.13.2025

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

10.09.2025

Pfizer Declares Fourth-Quarter 2025 Dividend

09.30.2025

Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

09.25.2025

Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

09.23.2025

Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

09.22.2025

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio